Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21

[Image: see text] Fibroblast growth factors 19 and 21 (FGF19 and FGF21) have biological actions that render them promising clinical candidates for treatment of metabolic diseases, particularly dyslipidemia and nonalcoholic steatohepatitis (NASH). These two atypical endocrine FGFs employ an accessory...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ACS Pharmacol Transl Sci
Autori principali: Pan, Jia, Parlee, Sebastian D., Brunel, Florence M., Li, Pengyun, Lu, Wei, Perez-Tilve, Diego, Liu, Fa, Finan, Brian, Kharitonenkov, Alexei, DiMarchi, Richard D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Chemical Society 2020
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7551714/
https://ncbi.nlm.nih.gov/pubmed/33073195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.0c00100
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi